Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human...

Area of Science:

• Molecular Biology
• Cancer Biology
• Immunology

Background:

• Bcl-2 protein inhibits apoptosis, but often only delays cell death in response to chemotherapy.
• In vivo survival signals, such as CD40 ligation on B-lymphocytes, can also promote resistance.
• The germinal center (GC) microenvironment provides survival signals that may enhance drug resistance.

Purpose of the Study:

• To investigate if combining Bcl-2 expression with GC-mimicking conditions (CD40 ligation and IL-4) enhances B lymphoma cell resistance to drug-induced apoptosis.
• To examine the effects of Bcl-2 overexpression and GC signals on cellular response and long-term survival after chlorambucil (CMB) treatment.

Main Methods:

• A Burkitt lymphoma (BL) cell line was transfected with human bcl-2 (BL-bcl-2) or a control plasmid (BL-Sv2).
• Cells were treated with the DNA-alkylating drug chlorambucil (CMB) in the presence or absence of CD40 ligation and IL-4.
• Apoptosis, cell cycle arrest (G2/M), protein levels (p53, Bcl-xL), and clonogenicity were analyzed.

Main Results:

• CMB treatment induced G2/M cell cycle arrest and apoptosis in both cell lines.
• Bcl-2 overexpression delayed CMB-induced cell death (50% death at 6 days vs. 2 days for control).
• CD40 ligation alone reduced apoptosis in BL-Sv2 cells (78% to 38%) and elevated Bcl-xL.
• The combination of Bcl-2 and CD40 ligation maximally reduced apoptosis (to 17%) and significantly increased clonogenic survival after CMB treatment.

Conclusions:

• Bcl-2, IL-4, vascular cell adhesion molecule-1, and CD40 ligation modulate the kinetics of drug-induced apoptosis.
• These factors, particularly CD40 ligation possibly via Bcl-xL, act synergistically to promote long-term survival and clonogenicity following DNA damage.
• The findings have significant implications for understanding and improving chemotherapy strategies against B-cell lymphomas.